SCHOTT Pharma invests $371m in NC for new syringe manufacturing facility, creating 400 jobs and producing mRNA, GLP-1 syringes by 2027.
SCHOTT Pharma plans to invest $371m in a new syringe manufacturing facility in Wilson, NC, creating 400 jobs. The facility will produce pre-fillable polymer syringes for mRNA medications and glass pre-fillable syringes for GLP-1 therapies, aiming to meet growing demand, reduce lead times and transportation costs, and prevent future drug shortages. The project is expected to commence operations in 2027.
March 18, 2024
9 Articles